The aim of thrombolytic therapy for acute myocardial infarction with plasminogen activators such as streptokinase is to lyse the coronary thrombus and reestablish blood flow as quickly as possible so that heart tissue loss is minimized and mortality rates are improved. Streptokinase has been encapsulated in large unilamellar phospholipid vesicles and tested in an animal model of acute myocardial infarction. The time required to restore vessel patency has been reduced more than 50%S when compared with findings for free streptokinase. The total dosage of streptokinase required was lower, and smaller remnant thrombi were observed with the encapsulated agent. Results from this initial unoptimized study may have significant implications for further reduction in mortality from heart attacks by therapy with plasminogen activators. (Circulation Research 1990;66:875-878) T he formation of an occlusive thrombus within an atherosclerotic coronary artery is a principal event initiating acute myocardial infarction.1-3 Recently developed therapeutic approaches useful for the rapid restoration of vessel patency in patients, along with a decreased mortality and improved ventricular function, have included the use of fibrinolytic agents, or, more precisely, plasminogen activators. By effecting the conversion of plasminogen to plasmin, the fibrinolytic agents act to stimulate the body's own system for dissolving clots and thereby, ideally, reestablish coronary artery blood flow. Plasminogen activators such as streptokinase (SK), urokinase, tissue plasminogen activator, and genetically engineered one-and two-chain versions of tissue plasminogen activator and urokinase have been administered effectively by intravenous infusion over a wide range of dosages. All of these agents show similar incidences and rates of reperfusion and problems with bleeding complications.4,5
Materials and Methods Preparation of Liposomes
Large unilamellar phospholipid vesicles were prepared through the detergent removal method. 1,l6 Briefly, a solution of 1-palmitoyl-2-oleoyl-phosphatidylcholine (PC; 50 mg) in 2.5 ml chloroform/ methanol (1:1 vol/vol) in a 10-ml Pyrex test tube was evaporated with a stream of nitrogen and lyophilized overnight. The thin film of dried PC was then resuspended in 1 ml of 3.29 M n-octyl-,3-D-glucopyranoside (OG) in Tris-buffered saline (TBS [20 mM Tris-HCl at pH 7.5 plus 100 mM NaCl]) by warming at 370 C for 2 hours with frequent stirring. After the PC had completely dissolved, 1.5 Liposomal enclosure of the plasminogen activator clearly increased the effectiveness of SK in this canine model, because lower total dosages of the encapsulated material were needed to reestablish blood flow. In these preliminary, unoptimized experiments, average total free SK administered equaled 170,500 units compared with 81,900 units of LESK. Furthermore, the sizes of the remnant thrombi, which were isolated from the excised coronary segment, seemed to confirm the accelerated thrombolysis, although the data were incomplete ( Table 1 ). The residual clots were smaller, even though dosages and time of action for LESK were reduced. Most important, encapsulation of SK shortened the time needed for reperfusion by more than one half.
Discussion
Time is of critical importance to acute myocardial infarction patients for two reasons. First, the extent to which the myocardial tissue can be salvaged decreases with time, and second, the rate of recanalization decreases with time because the effectiveness of thrombolysis declines. In general, thrombolytic therapy is believed to be beneficial to myocardium recovery for a period up to 6 hours. 3, 20, 21 Earlier and more recent work in the dog, however, suggests that major tissue damage occurs at shorter time periods. For example, it has been found that 30-40% of the infarcted area is lost at 40 minutes, and 80-90% is lost at 3 hours.10 Though one should be cautious in applying these results to patients,21 recent clinical studies support the contention that myocardium loss is rapid and significant before the 3-6-hour period. 22 The mechanism by which liposome encapsulation acts to accelerate thrombolysis in vivo is not clear. As noted above, we suspect that isolating SK in liposomes reduces its inactivation by plasma proteins (as seen in in vitro experiments15), retards SK initiation of systemic reactions, and prevents depletion or inactivation of key components of the fibrinolytic system. For example, computer models by our group suggest that present clinical dosages cause rapid formation of SK-plasminogen complex, depletion of free plasminogen available for activation, and, hence, low levels of plasmin. According to the model, the slow release of SK from the liposomes would tend to lower the concentration of the complex while raising that of plasmin. This different profile of fibrinolytic components could shift the mechanism of lysis from one principally of activation of clot-bound plasminogen to one with an increased role for circulating plasmin. Other possibilities are that the liposomes facilitate delivery of SK to or into the clot by concentrating near the clot and/or by preferentially releasing SK as the vesicles experience flow stress as they pass the thrombus. It also cannot be ruled out on the basis of the evidence presented here whether or not the reduced reperfusion time is a result of some action of intact liposomes or even dispersed phospholipids in concert with free SK. Additional work is necessary to determine which, if any, of these mechanisms explains the accelerated thrombolysis by encapsulation.
Lastly, it is unlikely that the results of these initial experiments reflect the greatest possible reduction in reperfusion times. For example, tissue plasminogen activator and urokinase exhibit greater binding affinity for fibrin than SK, as well as an enhanced ability to activate clot-bound plasminogen.4 Consequently, these activators may display more rapid thrombolysis, particularly when protected from inactivation within liposomes. Whether or not even faster reperfusion is realized, it is clear that liposomal encapsulation of SK or other plasminogen activators shows promise in the treatment of acute myocardial infarction.
